Tiny Health Secures $33 Million Series B Led by B Capital to Scale Gut Testing

Austin-based Tiny Health has secured $33 million in Series B funding led by B Capital, bringing its total capital raised to $46 million. The company plans to scale its B2B testing arm and clinical research initiatives as it leverages a dataset of nearly 200,000 microbiome samples

VentureGrill Desk
Updated Nov 13, 2026 2 min read
Tiny Health Secures $33 Million Series B Led by B Capital to Scale Gut Testing

Austin-based Tiny Health has closed a $33 million Series B funding round led by B Capital, according to Crunchbase News. The financing brings the healthtech startup’s total venture backing to $46 million, following a $4.5 million seed round in 2021 and an $8.5 million Series A in late 2023. Existing investors Spero Ventures, The Venture City, and Overwater Ventures participated in the round, joined by new investors Black Opal Ventures and Alumni Ventures. As part of the deal, B Capital’s Nick Whitehead will join the company’s board.

Tiny Health differentiates its platform through shotgun metagenomic sequencing, a method that analyzes microbial DNA to provide a broader view of gut health than limited-scope tests. While the company initially focused on infant microbiome testing, adults have since become its largest segment. Founder Cheryl Sew Hoy notes that the company positions itself as a wellness test rather than a diagnostic tool, providing actionable, evidence-backed insights. The company has collected nearly 200,000 microbiome samples to date, creating a proprietary dataset it intends to leverage for future predictive health capabilities.

The company is aggressively scaling its B2B arm, "Powered by Tiny," which allows healthcare providers and corporate partners to incorporate gut testing into their own service offerings. According to Crunchbase News, this division grew fourfold last year. The startup currently serves more than 6,000 practitioners and has secured partnerships with entities including Superpower, Fullscript, and Mayo Clinic’s Executive Health and Longevity Programs. This enterprise-focused growth strategy is a primary pillar for the new capital deployment, alongside plans to hire 30 additional employees to bolster its current team of 40.

For B Capital, the investment thesis centers on the growing consumer appetite for preventive health data. Nick Whitehead, senior principal at the firm, noted that consumers are increasingly paying out of pocket for health intelligence, such as wearables and blood panels, to preemptively manage their health. B Capital’s diligence process highlighted Tiny Health’s strong reputation among clinicians, with Whitehead describing the platform as the test consistently rated highest by the practitioners the firm consulted. The firm views the company’s ability to translate complex microbiome science into actionable consumer products as a category-defining opportunity.

Looking ahead, the company is developing "TinyAI," a tool designed to draw on its extensive sample library and scientific research to help users interpret their results. The firm intends to allocate $5 million of the new funding toward a specific research program aimed at determining whether microbiome-guided interventions can demonstrably improve health outcomes. While the company has published four scientific papers to date, the ability to prove clinical utility remains a critical benchmark for its long-term goal of identifying health risks before conditions develop.

Sources

  1. 01 Tiny Health Raises $33M To Explore What Gut Data Can Reveal About Future Health — Crunchbase News